GenoME Diagnostics, an investee company within the Deepbridge Life Sciences EIS portfolio, has recently won the 'Best EIS Investee Company' award at the 2023 EISA Awards, that took place at House of Lords on Thursday 22nd June.  

EISA (Enterprise Investment Scheme Association) commented: 

“The standard of businesses in this category was of an extremely high level; every finalist company, in their way, are drivers of leading innovation that will shape the future of their respective fields. The talent represented in this category made the judging decision challenging in the sense that the quality of each company was so high that we had to approach the decision with a fine-tooth comb. In that respect, each shortlisted business deserves celebration. The winner was very strong across all criteria and really impressed the judges – a very exciting company with huge potential!” 

The 2023 EISA Awards denote excellence in a number of EIS/SEIS fields and recognize the achievements of EIS/SEIS practitioners during the past year.  

Deepbridge Capital was also highly commended for ‘Best SEIS Investment Manager’, an award that underscores the importance of supporting early stage businesses at the outset and the compound effects this can have. 

About GenoME Diagnostics: 

GenoME Diagnostics Ltd is a spin-out of Queen’s University Belfast, founded off the back ofa decade of scientific research at the prestigious Patrick G Johnston Centre for Cancer Research. 

GenoMe are currently developing its lead product – OvaME, a blood test for earlier and more accurate diagnosis of ovarian cancer. The Company’s mission is to improve the ovarian cancer diagnostic pathway. 

Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).